Inventory Disclosure [Abstract] Inventory Inventory Disclosure [Text Block] Payables and Accruals [Abstract] Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities [Text Block] The entire disclosure for accrued liabilities and other current liabilities at the end of the reporting period. Quarterly Financial Information [Abstract] Unaudited Quarterly Results [Abstract] Schedule of quarterly financial information Schedule of Quarterly Financial Information [Table Text Block] Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities [Table Text Block] Tabular disclosure of the components of accrued liabilities and other current liabilities. Research and development Research and Development Revenue Revenue earned during the period arising from services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts and any other contract related to a particular project or product. Selling, general and administrative expense Selling, General and Administrative Expense Research and development expense Research and Development Expense Patent preparation fees Patent Preparation Fees The aggregate costs incurred for fees associated with the protection and expansion of patents and related intellectual property. Litigation accrual expense Loss Contingency, Loss in Period Operating loss Operating Income (Loss) Net income (loss) Net Income (Loss) Attributable to Parent Earnings Per Share, Basic and Diluted Earnings Per Share, Basic and Diluted Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Lab equipment [Member] Lab equipment [Member] Long lived, depreciable assets that are used in the laboratory. Computer Equipment [Member] Computer Equipment [Member] Furniture and Fixtures [Member] Furniture and Fixtures [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Property, plant and equipment, useful life Property, Plant and Equipment, Useful Life Receivables percentage Receivables Percentage Percentage of accounts receivables represented from National Institutes of Health and BARDA. Document and Entity Information [Abstract] Document and Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Public Float Entity Public Float Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Litigation Case [Axis] Litigation Case [Axis] Litigation Case Type [Domain] Litigation Case [Domain] License Agreement litigation License Agreement Litigation [Member] License Agreement Litigation [Member] Litigation Status [Axis] Litigation Status [Axis] Litigation Status [Domain] Litigation Status [Domain] Pending litigation Pending Litigation [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Surety bond Surety Bond [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other assets Other Assets [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Percentage of net profits from sales after net profit threshold Percentage of Net Profits from Sales After Net Profit Milestone Resulting From Award Damages The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale. Net profit threshold Net Profit Milestone The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale Equitable payment stream following first commercial sale, duration Duration of Equitable Payment Stream Following First Commercial Sale The Delaware Court of Chancery awarded to PharmAthene an equitable payment stream or equitable lien consisting of fify percent of the net profits that the Company achieves from sales of ST-246 after the Company secures $40 million in net profits, for ten years following the first commercial sale. Percentage of litigation costs awarded Litigation Costs Awarded, Percentage The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses. Plaintiff attorneys' fee and expenses Amount Plaintiff May Recover The Delaware Court of Chancery awarded PharmAthene one-third of its reasonable attorneys' fees and expert witness expenses. Payment to post collateral for surety bond Payment to Post Collateral for Surety Bond Payment to post collateral for surety bond. Collateral Collateral Percentage of cash collateral for surety bond. Surety bond Surety bond Amount of surety bond. Liabilities subject to compromise, loss contingency legal fees Liabilities subject to compromise, loss contingency legal fees The amount of pre-petition loss contingency liability representing legal and expert fees accrued and included in liabilities subject to compromise. Final order and judgment Final Order And Judgment Final order and judgment entered by the Court awarding damages to the Plaintiff. Loss contingency, accrual Loss Contingency Accrual Final order and judgment pre and post-judgment Interest Final Order And Judgment Pre and Post-Judgment Interest Final Order and Judgment entered by the Court awarding expectation damages, plus pre and post-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff. Final order and judgment including interest Final order and judgment plus interest Final Order and Judgment entered by the Court awarding expectation damages, plus pre-judgment interest, and certain permitted legal fees, costs, and expenses to Plaintiff. Final order and judgment post-judgment interest Final Order And Judgment Post-Judgment Interest Final order and judgment post-judgment interest entered by the Court awarding damages to the Plaintiff. Statement of Cash Flows [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash used in operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and other amortization Depreciation, Depletion and Amortization Increase (decrease) in fair value of warrants Increase In Fair Value Of Warrants Noncash expense, not otherwise specified in the taxonomy, charged against earnings in the period to adjust the fair market value of liability classified warrants to purchase common stock. Stock-based compensation Share-based Compensation Gain on sale of assets Gain (Loss) on Disposition of Assets Loss on disposal of assets Loss On Disposal Of Assets Amount of loss on disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. Non-cash interest expense Other Noncash Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Deferred costs Increase (Decrease) in Deferred Charges Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense Other assets Increase (Decrease) in Other Operating Assets Deferred income taxes, net Deferred Income Tax Expense (Benefit) Accounts payable, accrued expenses and other current liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Liabilities subject to compromise Liabilities Subject to Compromise, Period Increase (Decrease) Deferred revenue Increase (Decrease) in Deferred Revenue Other liabilities Increase (Decrease) in Other Operating Liabilities Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Capital expenditures Payments to Acquire Property, Plant, and Equipment Proceeds from sale of assets Proceeds from Sale of Productive Assets Restricted Cash Payments for (Proceeds from) Other Investing Activities Net cash (used in) provided by investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net proceeds from exercise of warrants and options Proceeds From Issuance Of Warrants and Options The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Payment of common stock tendered for employee tax obligations Payments Related to Tax Withholding for Share-based Compensation Proceeds from issuance of long-term debt Proceeds from Issuance of Long-term Debt Repayments of long-term debt Repayments of Long-term Debt Change in excess tax benefit stock-based compensation, financing activities Change In Excess Tax Benefit Stock-Based Compensation, Financing Activities Amount of cash inflow/(outflow) from realized tax benefit related to deductible compensation cost reported on the entity's tax return for equity instruments in excess of the compensation cost for those instruments recognized for financial reporting purposes. Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents at beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents at end of period Supplemental disclosure of non-cash financing activities: Supplemental Cash Flow Information [Abstract] Reclass of common stock warrant liability to additional paid-in capital upon warrant exercise Reclass of Common Stock Warrant Liability To Additional Paid In Capital Upon Exercise Value of reclass of common stock warrant liability to additional paid-in capital upon exercise in noncash financing activities. Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Performance Shares [Member] Performance Shares [Member] Award Type [Axis] Award Type [Axis] Award Type [Domain] Equity Award [Domain] Stock Options Employee Stock Option [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of shares authorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Stock-based compensation expense Allocated Share-based Compensation Expense Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of shares outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Number of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Number of shares exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Number of shares canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Number of shares outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted average exercise price outstanding at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted average exercise price, granted Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average exercise price, exercised Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Weighted average exercise price, canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Weighted average exercise price outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining life, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Number of shares vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Weighted average exercise price, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average remaining life, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Intrinsic value, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Number of shares exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted average exercise price, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted average remaining life, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Intrinsic value, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Unrecognized stock-based compensation cost, net of estimated forfeitures Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Weighted average remaining requisite service period (in years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Fair value of vested stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Total intrinsic value of stock options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Performance-based stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Performance Based, Number The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date subject to performance conditions under the option plan. Performance-based stock options exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options Exercisable, Performance Based, Number The number of shares exercisable as of the balance sheet date related to performance conditions met under the option plan. Statement of Financial Position [Abstract] ASSETS Assets [Abstract] Cash and cash equivalents Restricted cash Restricted Cash and Cash Equivalents, Noncurrent Accounts receivable Accounts Receivable, Net, Current Inventory Inventory, Net Prepaid expense and other assets, current Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property, plant and equipment, net Property, Plant and Equipment, Net Deferred costs Deferred Costs, Noncurrent Goodwill Goodwill Other assets Other Assets, Noncurrent Total assets Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Accounts payable Accounts Payable, Current Accrued expenses and other current liabilities Accrued Liabilities, Current Long-term debt, current maturities Long-term Debt, Current Maturities Total current liabilities Liabilities, Current Deferred revenue Deferred Revenue, Noncurrent Deferred income tax liability Deferred Tax Liabilities, Net, Noncurrent Other liabilities Other Liabilities Liabilities subject to compromise Liabilities Subject to Compromise Total liabilities Liabilities Stockholders' equity Stockholders' Equity Attributable to Parent [Abstract] Common stock ($.0001 par value, 100,000,000 shares authorized, 54,114,296 and 53,504,296 issued and outstanding at December 31, 2015, and December 31, 2014, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders' equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders' equity Liabilities and Equity Equity [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Fair Value, Measurements, Recurring [Member] Fair Value, Measurements, Recurring [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value, Inputs, Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Scenario [Axis] Scenario [Axis] Scenario, Unspecified [Domain] Scenario, Unspecified [Domain] Extended Expiration Period [Member] Extended Expiration Period [Member] Extended Expiration Period [Member] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Capital units, authorized Capital Units, Authorized Common stock, shares authorized Common Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Authorized Change In fair value of common stock warrants Change In Fair Value Of Common Stock Warrants The aggregate adjustment to the fair market value of liability classified warrants to purchase common stock. Warrants to purchase common stock Class of Warrant or Right, Number of Securities Called by Warrants or Rights Exercise price of warrants to purchase common stock Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants contractual term (in years) Warrants contractrual term The contractual life of warrants. Commitment to Invest Commitment to Invest Related party commitment to invest at the Company's discretion in exhange for common stock and warrants. Service Agreement Term Service Agreement Term 1 Service agreement, entered into with MacAndrews & Forbes LLC ("M&F"), in years. Warrants to purchase percentage of acquired shares Warrants to Purchase Percentage of Shares Related party commitment to invest at the Company's discretion in exhange for warrants to purchase a percentage of the number of Company shares acquired by the related party. Proceeds from issuance of warrants and options Proceeds From Issuance Of Warrants and Options 1 The cash inflow associated with both the amount received from holders exercising their stock options and issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately. Common stock, shares issued Common Stock, Shares, Issued Expense of Warrants Held as Assets Expense of Warrants Held as Assets The expense associated with warrants held as assets. Organization and Basis of Presentation [Abstract] Organization and Basis of Presentation [Abstract] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event [Member] Subsequent Event [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Bankruptcy claims, number of claims outstanding Bankruptcy Claims, Number Of Claims Outstanding The aggregate number of claims outstanding with the bankruptcy court. Payment to extend days to satisfy claim Payment To Extend Days To Satisfy Claim Total amount of payment to PharmAthene to extend the number of days to satisfy the claim. Amount to be paid on effective date of plan of reorganization Amount To Be Paid On Effective Date of Plan Of Reorganization The amount the Company is to pay PharmAthene on the effective date of the plan of reorganization. Bankruptcy claims, all other liquidated proof of claims Bankruptcy claims, all other liquidated proof of claims The total dollar value of all other liquidated proof of claims, outside of the litigation. Proof Of Claim Asserted In Connection With Litigation Proof Of Claim Asserted In Connection With Litigation Proof of claim asserted in connection with litigation field with the Bankruptcy Court. Debt satisfied Debt Satisfied The Company was authorized by the Bankruptcy Court to satifsy a fully-secured term loan. Prepetition claim satisfied Prepetition Claim Satisfied The Company has satisfied a prepetition claim as part of the assumption of the Commercial Manufacturing Agreement, as amended, pursuant to orders of the Bankruptcy Court. Rent reduction Rent Reduction The amount of reduced monthly rent for the research and development facility due to the addendum to the Commercial Lease. Proof of claim, withdrawn Proof of Claim, Withdrawn Proof of claim from commercial lease for research facility, withdrawn. Bankruptcy claims, amount of unliquidated claim Bankruptcy claims, amount of unliquidated claim The amount of unliquidated proof of claim filed with the Bankruptcy Court. Net capital deficiency Net Capital Deficiency Net Capital Deficiency. Net capital is equal to the net worth of the broker dealer, less certain items such as exchange memberships, carrying value of securities not readily marketable, haircuts on marketable securities in proprietary accounts, furniture and equipment and other illiquid assets as defined. Bonus Accrued Bonuses, Current Professional fees Accrued Professional Fees, Current Vacation Accrued Vacation, Current Other Other Accrued Liabilities, Current Total Restricted Stock Units (RSUs) [Member] Restricted Stock Units (RSUs) [Member] Award vesting period Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward] Number of shares granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Number of shares canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Number of shares outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price [Roll Forward] Weighted average grant-date fair value, granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average grant-date fair value, vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Weighted averaged grant-date fair value, canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Weighted average grant-date fair value outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unrecognized stock-based compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Weighted average remaining requisite service period Fair value of stock compensation vested Stock Issued During Period, Value, Restricted Stock Award, Gross Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Term loan Debt, Long-term and Short-term, Combined Amount Term loan, fixed interest rate Long-term Debt, Percentage Bearing Fixed Interest, Percentage Rate Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Loan, period Loan Term Term of the loan in years. Cash Collateral for Borrowed Securities Cash Collateral for Borrowed Securities Stock options activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Stock appreciation rights award activity Schedule of Share-based Compensation, Stock Options and Stock Appreciation Rights Award Activity [Table Text Block] Restricted stock and restricted stock units activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Quarterly Financial Information Quarterly Financial Information [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Appreciation Rights (SARs) [Member] Stock Appreciation Rights (SARs) [Member] Restricted Stock Units (RSUs) Warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Anti-dilutive employee share-based awards, excluded Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Maximum number of shares to be issued Share-based Compensation Arrangement by Share-based Payment Award, Maximum Number of Shares that Could Be Issued Share-based compensation arrangement by share-based payment award, maximum number of shares that could be issued Number of shares exercised Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercised in Period The number of exercises made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Weighted average exercise price granted Share-based Compensation Arrangement by Share-based Payment Award, Options Granted, Weighted Average Excercise Price The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of granted options under the stock option plan. Weighted average exercise price exercised Share-based Compensation Arrangement by Share-based Payment Award, Options Excercised, Weighted Average Excercise Price The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of exercised options under the stock option plan. Weighted average exercise price canceled and expired Share-based Compensation Arrangement by Share-based Payment Award, Options Canceled / Expired, Weighted Average Excercise Price The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of canceled and expired options under the stock option plan. Weighted average exercise price outstanding at end of period Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Weighted Average Exercise Price The weighted-average price at which grantees can acquire the shares reserved for issuance under the stock option plan. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Intrinsic value outstanding Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Intrinsic Value Amount of difference between fair value of the underlying equity instruments reserved for issuance and exercise price of equity instruments outstanding. Weighted average exercise price, vested and expected to vest Share-based Compensation Arragement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Weighted Average Excercise Price As of the balance sheet date, the weighted average excercise price for outstanding equity instruments other than options that are fully vested of expected to vest. Weighted average remaining life, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Weighted Average Remaining Life The weighted-average remaining life in years, for equity instruments other than options vested and expected to vest. Intrinsic value, vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share Number of shares exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other then Options, Exercisable Number The number of shares into which fully or partially vested, other than stock (or unit) option plans outstanding as of the balance sheet date can be currently converted under the option plan. Weighted average exercise price, exercisable Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Exercisable Options, Weighted Average Exercise Price Weighted average remaining life, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Weighted Average Remaining Life The weighted-average remaining life in years, for excercisable equity instruments other than options. Intrinsic value, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable, Intrinsic Value Amount of difference between fair value of the underlying equity instrument for the issuance and exercise price of vested portions of equity instruments outstanding and currently exercisable. Fair value of vested stock appreciation rights Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total intrinsic value of stock appreciation rights exercised Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Exercises in Period, Intrinsic Value Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on equity, other than options exercised (or share units converted) into shares. Balance Sheet Parenthetical [Abstract] Balance Sheet Parenthetical [Abstract] Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares outstanding Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Income Tax Disclosure [Text Block] Research and Development [Abstract] Procurement Contract [Table] Procurement Contract [Table] Procurement Contract [Table] Procurement Contract [Axis] Procurement Contract [Axis] Procurement Contract [Axis] Procurement Contract [Domain] Procurement Contract [Domain] Procurement Contract [Domain] BARDA Contract Barda Contract [Member] Barda Contract [Member] Procurement Contract [Line Items] Procurement Contract [Line Items] Procurement Contract [Line Items] Number of courses to be delivered Number of Courses To Be Delivered 1 Number of tecovirimat, also known as ST-246, courses to be delivered to the U.S. Strategic National Stockpile Value of contract Government Contract, Value of Award 1 Value of base contract award. Contract value of manufacturing and delivery activities Contract Value of Manufacturing and Delivery Activities Contract value of manufacturing and delivery activities. Contract value of development and support activities Contract Value of Development and Support Activities Contract value of development and support activities Contract value of various options Contract Value of Various Options Contract value of various options exercisable at BARDA's discretion. Contract value, option, FDA approval Contract Value, Option, FDA Approval Contract value of option exercisable, FDA approval for extension to 84-month expiry for Tecovirimat, at BARDA's discretion. Contract value, detail of option exercisable, development activities Contract Value, Detail Of Option Exercisable, Development Activities Contract value of option exercisable, amount represents exercisable option that would fund development and support activities, at BARDA's discretion. Contract value, detail of option exercisable, production activities Contract Value, Detail Of Option Exercisable, Production Activities Contract value of option exercisable, amount represents exercisable option that would fund production activities, at BARDA's discretion. Number of courses under modified contract Government Contract, Number of Courses Purchased Under Modified Contract Government contract, number of courses to be purchased under modified contract. Number of courses manufactured using federal funds Government Contract, Number of Courses Manufactured Using Federal Funds Government contract, number of courses to be delivered that were manufactured using federal funds under prior development contracts. Proceeds from manufacture and physical delivery of course, government contractses Proceeds From Manufacture And Physical Delivery Of Courses, Government Contracts Proceeds from manufacture and physical delivery of courses, government contracts. Proceeds from advance payments under the BARDA contract Proceeds from Advance Payments, Government Contracts Proceeds from advance payments, government contracts Milestone payment Milestone payment Proceeds from milestone payment, Government contracts Proceeds from physical delivery of courses, government contracts Proceeds From Physical Delivery Of Courses, Government Contracts Proceeds from physical delivery of courses, government contract. Courses delivered Number of courses delivered and accepted Number of tecovirimat, also known as ST-246, courses delivered and accepted to the U.S. Strategic National Stockpile. Government contract, number of free courses delivered and accepted Government Contract, Number of Free Courses Delivered and Accepted Number of courses of tecovirimat delivered and accepted to the Strategic Stockpile at no cost to the government. Number of courses delivered and accepted at provisional dosage, once daily Number Of Courses Delivered And Accepted At Provisional Dosage, Once Daily Number of tecovirimat, also known as ST-246, courses delivered and accepted at the provisional dosage of 600 mg once daily to the U.S. Strategic National Stockpile. Courses delivered provisional dosage, twice daily Courses Delivered Provisional Dosage, Twice Daily Courses of tecovirimat delivered to the Strategic Stockpile at the provisional dosage of 600 mg twice daily (1,200 mg per day). Contract receivable collected, delivered products Contract Receivable Collected Delivered Products Amount billed to customers under contracts or programs and collected for delivered product. Excludes amounts due that have been withheld because of retainage provisions in a contract. Contract receivable collected for reimbursed R&D and supportive studies Contract receivable collected, research and developemnt services Amount billed to customers under long-term contracts or programs and collected for research and development services. Excludes amounts due that have been withheld because of retainage provisions in a contract. Contract Receivable Collected, Research and Development Services Since Inception Contract Receivable Collected, Research and Development Services Since Inception Amount billed to customers under long-term contracts or programs and collected for research and development services, since inception. Excludes amounts due that have been withheld because of retainage provisions in a contract. Procurement contract deferred cost, noncurrent Procurement Contract Deferred Cost, Noncurrent Sum of the carrying amounts of deferred costs, for only the procurement contract, that are expected to be recognized as a charge against earnings in periods after one year or beyond the normal operating cycle, if longer. Deferred revenue Deferred Revenue, Additions Government Contract, number of courses delivered Government Contract, number of courses delivered Courses of Arestvyr delivered to the Strategic Stockpile Research and development revenue long-term contract Research and Development Revenue Long-term Contract Revenue earned during the period arising from research and development services provided under the terms of a long-term contract. May include government contracts and any other contract related to a particular project or product. Number of active contracts Number of Active Contracts Number of active contracts. Number of active grants Number of Active Grants Number of active grants Potential future research and development funding Potential Future Aggregate Research and Development Expenses Potential future aggregate research and development funding for specific projects which includes options that may or may not be exercised at the U.S. government's discretion. Schedule of components of income tax expense (benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of effective income tax rate reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Debt Debt Disclosure [Text Block] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Current federal tax expense (benefit) Current Federal Tax Expense (Benefit) Current state and local tax expense (benefit) Current State and Local Tax Expense (Benefit) Current income tax expense (benefit) Current Income Tax Expense (Benefit) Deferred federal income tax expense (benefit) Deferred Federal Income Tax Expense (Benefit) Deferred state and local income tax expense (Benefit) Deferred State and Local Income Tax Expense (Benefit) Deferred income tax expense (benefit) Benefit from (provision for) income taxes Income Tax Expense (Benefit) Deferred tax assets: Components of Deferred Tax Assets [Abstract] Deferred tax assets, net operating losses Deferred Tax Assets, Operating Loss Carryforwards Deferred tax assets, capitalized research and development costs Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs Deferred tax assets, amortization of intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Deferred tax assets, share-based compensation cost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Deferred tax assets, property, plant and equipment Deferred Tax Assets, Property, Plant and Equipment Deferred tax assets, deferred income Deferred Tax Assets, Deferred Income Deferred tax assets, alternative minimum tax Deferred Tax Assets, Tax Credit Carryforwards, Alternative Minimum Tax Deferred tax assets, contingencies Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Contingencies Deferred tax assets, other Deferred Tax Assets, Other Deferred tax assets, gross Deferred Tax Assets, Gross Deferred tax assets, valuation allowance Deferred Tax Assets, Valuation Allowance Deferred tax assets, net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Deferred tax liabilities: Components of Deferred Tax Liabilities [Abstract] Deferred tax liabilities, goodwill Deferred Tax Liabilities, Goodwill Deferred tax liabilities, capitalized contract costs Deferred Tax Liabilities, Capitalized Contract Costs Amount of deferred tax liability attributable to taxable temporary differences from capitalized contract costs. Deferred tax liabilities, other Deferred Tax Liabilities, Other Deferred Tax Liabilities, Net Deferred Tax Liabilities, Net Loss accrual for expectation damages Loss Accrual, Expectation Damages Loss accrual for expectation damages. Valuation allowance, deferred tax asset, explanation of change Valuation Allowance, Deferred Tax Asset, Explanation of Change Valuation allowance, increase amount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Federal net operating loss carryforwards Operating Loss Carryforwards Operating loss carryforwards, subject to limitations Deferred Tax Assts, Operating Loss Carryforwards, Subject to Limitations Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to annual limitations. Operating loss carryforwards from excess tax deductions on stock option activity Adjustments to Additional Paid in Capital, Income Tax Benefit from Share-based Compensation Effective Income Tax Rate, Continuing Operations, Tax Rate Reconciliation [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] U.S. federal statutory taxes Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent State and local income taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Gain (loss) from fair value of common warrants Effective Income Tax Rate Reconciliation Loss From Fair Value of Common Warrants The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to changes in the fair value of common warrants. Share-based compensation cost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Percent Reorganization costs Effective Income Tax Rate Reconciliation Loss From Reorganization Costs The portion of the difference between the effective income tax rate and domestic federal statutory income tax rate attributable to changes in reorganization costs. Other adjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Change in deferred tax assets valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Stock Compensation Plans Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Income Statement [Abstract] Revenues Revenues [Abstract] Operating expenses Operating Expenses [Abstract] Selling, general and administrative Research and development Restructuring charges Restructuring Charges Total operating expenses Operating Expenses Operating loss Decrease (increase) in fair value of common stock warrants Non-cash interest expense Interest Expense Other income, net Nonoperating Income (Expense) Reorganization items, net Reorganization Items Loss before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest Benefit from (provision for) income taxes Net and comprehensive income (loss) Basic earnings (loss) per share Earnings Per Share, Basic Diluted earnings (loss) per share Earnings Per Share, Diluted Weighted average shares outstanding: basic Weighted Average Number of Shares Outstanding, Basic Weighted average shares outstanding: diluted Weighted Average Number of Shares Outstanding, Diluted Consolidated Statements of Changes in Stockholder's Equity [Abstract] Consolidated Statements of Changes in Stockholder's Equity [Abstract] Statement [Table] Statement [Table] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Statement [Line Items] Statement [Line Items] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Total stockholders' equity (in shares) Total stockholders' equity Issuance of common stock upon exercise of stock options and warrants (in shares) Issuance of common stock upon exercise of stock options and warrants Proceeds from Stock Options Exercised Stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Payment of common stock tendered for employee stock-based compensation tax obligations (in shares) Shares Paid for Tax Withholding for Share Based Compensation Payment of common stock tendered for employee stock-based compensation tax obligations Warrants issued in exchange for services recorded as other assets Issuance of Stock and Warrants for Services or Claims Fair value of exercised common stock warrants Proceeds from Issuance of Warrants Change in excess tax benefit stock-based compensation, Total stockholders' equity (in shares) Total stockholders' equity Property, Plant and Equipment [Abstract] Property, Plant and Equipment Property, Plant and Equipment Disclosure [Text Block] Inventory, Current [Table] Inventory, Current [Table] Inventory [Line Items] Inventory [Line Items] Number of courses delivered and accepted Work in process Inventory, Work in Process and Raw Materials Finished goods Inventory, Finished Goods, Net of Reserves Inventory write-downs Inventory Write-downs Inventory write-downs included in research and development expense on the balance sheet. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Reorganization [Abstract] Reorganization [Abstract] Debtor Reorganization Items, Legal and Advisory Professional Fees Debtor Reorganization Items, Legal and Advisory Professional Fees Reorganization, Professional Fees Reorganization, Professional Fees Amount of reorganization items related to professional fees related to entities in bankruptcy. Reorganization, Trustee fees Reorganization, Trustee fees Amount of reorganization items for trustee fees related to entities in bankruptcy. Debtor Reorganization Items, Other Expense (Income) Debtor Reorganization Items, Other Expense (Income) Reorganization Items Reorganization Payments Reorganization Payments The amount the Company paid for reorganization items. Use of Estimates Use of Estimates, Policy [Policy Text Block] Cash, Cash Equivalents, and Short-term Investments and Marketable Securities, Policy Cash, Cash Equivalents, and Short-term Investments [Text Block] Concentration of Credit Risk, Policy Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable, Policy Trade and Other Accounts Receivable, Policy [Policy Text Block] Inventory, Policy Inventory, Policy [Policy Text Block] Property, Plant and Equipment, Policy Property, Plant and Equipment, Policy [Policy Text Block] Liabilities Subject To Compromise, Policy Liabilities Subject To Compromise [Policy Text Block] [Policy Text Block] for liabilities that are subject to compromise. The Company's estimate of known or potential pre-petition claims to be resolved in connection with its chapter 11 case Revenue Recognition, Policy Revenue Recognition, Policy [Policy Text Block] Research and Development Expense, Policy Research and Development Expense, Policy [Policy Text Block] Reorganization Items, Policy Reorganization Items, Policy [Policy Text Block] Reorganization Items, represent costs directly attributable to the chapter 11 case and the implementation of the plan of reorganization are expensed as incurred as reorganization items Goodwill, Policy Goodwill, Policy [Policy Text Block] Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill. Share-based Compensation, Policy Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Income Tax, Policy Income Tax, Policy [Policy Text Block] Net Loss Per Share, Policy Earnings Per Share, Policy [Policy Text Block] Fair Value of Financial Instruments, Policy Fair Value of Financial Instruments, Policy [Policy Text Block] Legal Contingencies, Policy Commitments and Contingencies, Policy [Policy Text Block] Segment Reporting, Policy Segment Reporting, Policy [Policy Text Block] Recent Accounting Pronouncements, Policy New Accounting Pronouncements, Policy [Policy Text Block] Revenue, percentage Revenue Percentage Percentage of revenue represented from National Institutes of Health and BARDA. Liabilities Subject to Compromise [Abstract] Liabilities subject to compromise Reorganization under Chapter 11 of US Bankruptcy Code Disclosure [Text Block] Property, plant and equipment Property, Plant and Equipment [Table Text Block] Liabilies subject to compromise [Table Text Block] Liabilies subject to compromise [Table Text Block] [Table Text Block] for Schedule of liabilities that are subject to compromise. Reorganization items [Table Text Block] Reorganization items [Table Text Block] The schedule represents a summary of reorganization items. Leasehold improvements, gross Leasehold Improvements, Gross Computer equipment, gross Computer Equipment The gross amount of capitalized computer equipment costs as of the balance sheet date. Furniture and fixtures, gross Furniture and Fixtures, Gross Property, plant and equipment, gross Property, Plant and Equipment, Gross Accumulated depreciation, depletion and amortization, property, plant, and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Depreciation and other amortization Loss on disposal of assets Net book value of equipment sold Property, Plant and Equipment, Disposals Proceeds from sale of equipment Proceeds from Sale of Property, Plant, and Equipment Gain on sale of equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Rent expense Rent expense Facilities Lease Rental expense incurred for facilities leased. Operating leases, future minimum payments due, next twelve months Operating Leases, Future Minimum Payments Due, Next Twelve Months Operating leases, future minimum payments, due in two years Operating Leases, Future Minimum Payments, Due in Two Years Operating leases, future minimum payments, due in three years Operating Leases, Future Minimum Payments, Due in Three Years Operating leases, future minimum payments, due in four years Operating Leases, Future Minimum Payments, Due in Four Years Operating leases, future minimum payments, due in five years Operating Leases, Future Minimum Payments, Due in Five Years Operating leases, future minimum payments due Operating Leases, Future Minimum Payments Due Deferred revenue Liabilities subject to compromise, deferred revenue The amount of pre-petition deferred revenue included in liabilities subject to compromise. Accounts payable - pre-petition Liabilities subject to compromise, accounts payable The amount of pre-petition trade accounts payable included in liabilities subject to compromise. Expectation damages accrual- PharmAthene Litigation Legal and expert fees accrual - PharmAthene Litigation Liabilities subject to compromise, other accrued expense The amount of pre-petition accrued expense included in liabilities subject to compromise. Legal and expert fees accrual - PharmAthene Litigation Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Procurement Contract and Research Agreements Procurement Contract and Research Agreements [Text Block] The entire disclosure for procurement contracts and research agreements including grants or contracts from various agencies of the U.S. government to support the reporting entity's research and development activities. Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Member of Board of Directors Management [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Free rent period Free Rent Period Free Rent Period in months allowed under the sublease. Monthly rental payments first five years Monthly Rental Payments First Five Years The amount of the monthly rental payments due under the sublease entered into for the first five years. Initial rent period Initial Rent Period Represents the number of years for the initial rent period of five years and related monthly payments. Monthly rental payments after five years Monthly Rental Payments After Five Years The amount of the monthly rental payments due under the sublease entered into after the first five years. Rent period after first five years Rent Period After First Five Years Represents the amount of years after the initial rent period of first five years of which monthly rental payments will increase. Legal fees Legal Fees Accounts payable to related party Accounts Payable, Related Parties Schedule of Future Minimum Rental Payments for Operating Leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Inventory [Abstract] Inventory [Abstract] Inventory Schedule of Inventory, Current [Table Text Block] Stockholders' Equity Stockholders' Equity Note Disclosure [Text Block]